Abstract

The occurrence of invasive fungal infections represents a substantial threat to human health that is particularly serious in immunocompromised patients. The limited number of antifungal agents, devoid of unwanted toxic effects, has resulted in an increased demand for new drugs. Herein, the chalcone framework was functionalized to develop new antifungal agents able to interfere with cell growth and with the infection process. Thus, a small library of chalcone-based analogues was evaluated in vitro against C. albicans ATCC 10231 and a number of compounds strongly inhibited yeast growth at non-cytotoxic concentrations. Among these, 5 and 7 interfered with the expression of two key virulence factors in C. albicans pathogenesis, namely, hyphae and biofilm formation, while 28 emerged as a potent and broad spectrum antifungal agent, enabling the inhibition of the tested Candida spp. and non-Candida species. Indeed, these compounds combine two modes of action by selectively interfering with growth and, as an added value, weakening microbial virulence. Overall, these compounds could be regarded as promising antifungal candidates worthy of deeper investigation. They also provide a chemical platform through which to perform an optimization process, addressed at improving potency and correcting liabilities.

Highlights

  • Life-threatening invasive fungal infections (IFIs) have been widely recognized as the “hidden killers” of immunocompromised individuals such as patients subjected to organ transplantation and those affected by cancer or AIDS [1,2]

  • Some members of the library have been previously tested versus Leishmania donovani [17], and a number compounds endowed with encouraging in vitro activity were identified

  • Sixteen chalcones showed a good inhibitory activity against C. albicans control strain associated with a different degree of cytotoxicity towards mammalian cells

Read more

Summary

Introduction

Life-threatening invasive fungal infections (IFIs) have been widely recognized as the “hidden killers” of immunocompromised individuals such as patients subjected to organ transplantation and those affected by cancer or AIDS [1,2]. IFIs have become a severe health problem due to their association with high incidence and mortality [3]. One of the main consequences of the biofilm mode of growth is the enhanced resistance to host defense mechanisms and antifungal drugs, which is why biofilm-associated infections are frequently refractory to conventional therapy. Epidemiological data reveal that, C. albicans remains the most common species isolated in superficial and invasive fungal infections, the distribution is changing and other yeasts, including opportunistic and ubiquitous saprophytic fungus, are increasingly recovered in immunocompromised hosts, those with central venous catheters or other indwelling devices [5,6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call